Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing
Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Vinge advises Anyfin with application to conduct financing business

 Vinge has, together with PwC, advised Anyfin with regulatory advice in connection with Anyfin’s application to conduct financing business pursuant to the Banking and Financing Business Act (2004:297). The Swedish Financial Supervisory Authority granted the license on 17 June 2025.
June 25, 2025

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025